Skip to main content

Peer Review reports

From: A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany

Original Submission
18 Jan 2021 Submitted Original manuscript
7 Apr 2021 Reviewed Reviewer Report
10 Apr 2021 Reviewed Reviewer Report
5 May 2021 Author responded Author comments - Florian Kron
Resubmission - Version 2
5 May 2021 Submitted Manuscript version 2
28 Jun 2021 Reviewed Reviewer Report
10 Jul 2021 Reviewed Reviewer Report
13 Aug 2021 Author responded Author comments - Florian Kron
Resubmission - Version 3
13 Aug 2021 Submitted Manuscript version 3
Publishing
26 Aug 2021 Editorially accepted
9 Sep 2021 Article published 10.1186/s12913-021-06970-8

You can find further information about peer review here.

Back to article page